Neu Base Therapeutics, Inc. NBSE
We take great care to ensure that the data presented and summarized in this overview for NeuBase Therapeutics, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in NBSE
Top Purchases
Top Sells
About NBSE
NeuBase Therapeutics, Inc., a pre-clinical-stage biopharmaceutical company, focuses on the development of therapies to treat rare genetic diseases and cancers caused by mutant genes. The company's proprietary modular peptide-nucleic acid antisense oligo (PATrOL) platform focuses on addressing Huntington's disease (HD) and myotonic dystrophy, as well as other genetic disorders, and cancer and oncology applications. Its lead programs include NT0100, a PATrOL enabled anti-gene for Huntington's disease; NT0200, a PATrOL enabled anti-gene for myotonic dystrophy type 1; NT0300, a PATrOL-enabled therapeutic treatment to target the mutated KRAS gene. NeuBase Therapeutics, Inc. is headquartered in Pittsburgh, Pennsylvania.
Insider Transactions at NBSE
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Sep 18
2023
|
Symetryx Corp > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
50,000
-100.0%
|
$50,000
$1.19 P/Share
|
|
Sep 15
2023
|
Symetryx Corp > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
103,337
-67.39%
|
$103,337
$1.26 P/Share
|
|
Sep 14
2023
|
Symetryx Corp > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
129,108
-45.71%
|
$129,108
$1.44 P/Share
|
|
Sep 11
2023
|
Symetryx Corp > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
3,376
-0.71%
|
$3,376
$1.44 P/Share
|
|
Sep 08
2023
|
Symetryx Corp > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
128,847
-21.29%
|
$128,847
$1.53 P/Share
|
|
Sep 07
2023
|
Symetryx Corp > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
74,852
-11.01%
|
$74,852
$1.8 P/Share
|
|
Sep 01
2023
|
Symetryx Corp > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
61,076
+8.24%
|
$0
$0.98 P/Share
|
|
Aug 02
2023
|
Dietrich A Stephan Founder and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
93,234
+50.0%
|
$0
$0.02 P/Share
|
|
Mar 16
2023
|
Dietrich A Stephan Founder and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
153,000
+50.0%
|
-
|
|
Mar 16
2023
|
Todd P. Branning Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
54,200
+39.16%
|
-
|
|
Feb 13
2023
|
Dietrich A Stephan Founder and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
655,000
+30.8%
|
-
|
|
Sep 28
2022
|
Dietrich A Stephan Founder and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
750,000
+47.87%
|
-
|
|
Mar 30
2022
|
William Roland Mann Chief Operating Officer |
BUY
Open market or private purchase
|
Direct |
6,200
+35.63%
|
$6,200
$1.92 P/Share
|
|
Mar 18
2022
|
Todd P. Branning Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
10,000
+25.0%
|
$10,000
$1.81 P/Share
|
|
Mar 17
2022
|
Todd P. Branning Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
10,000
+33.33%
|
$10,000
$1.74 P/Share
|
|
Mar 16
2022
|
Todd P. Branning Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
10,000
+50.0%
|
$10,000
$1.62 P/Share
|
|
Mar 04
2022
|
Eric I Richman Director |
BUY
Open market or private purchase
|
Direct |
1,000
+2.18%
|
$1,000
$1.62 P/Share
|
|
Mar 03
2022
|
Eric I Richman Director |
BUY
Open market or private purchase
|
Direct |
1,300
+2.87%
|
$1,300
$1.72 P/Share
|
|
Mar 01
2022
|
Eric I Richman Director |
BUY
Open market or private purchase
|
Direct |
1,580
+3.57%
|
$1,580
$1.58 P/Share
|
|
Dec 31
2021
|
Dietrich A Stephan Founder and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
42,250
+38.75%
|
-
|
Last 12 Months Summary
| Exercise of conversion of derivative security | 93.2K shares |
|---|---|
| Open market or private purchase | 61.1K shares |
| Open market or private sale | 490K shares |
|---|